TVTX
Income statement / Annual
Last year (2024), Travere Therapeutics, Inc.'s total revenue was $233.18 M,
an increase of 60.55% from the previous year.
In 2024, Travere Therapeutics, Inc.'s net income was -$321.55 M.
See Travere Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$233.18 M |
$145.24 M |
$109.46 M |
$131.84 M |
$198.32 M |
$175.34 M |
$164.25 M |
$154.94 M |
$133.59 M |
$99.89 M |
| Cost of Revenue |
$7.74 M
|
$11.45 M
|
$4.42 M
|
$3.82 M
|
$6.13 M
|
$5.23 M
|
$5.53 M
|
$3.61 M
|
$4.55 M
|
$2.19 M
|
| Gross Profit |
$225.43 M
|
$133.79 M
|
$105.04 M
|
$128.02 M
|
$192.20 M
|
$170.10 M
|
$158.72 M
|
$151.33 M
|
$129.04 M
|
$97.71 M
|
| Gross Profit Ratio |
0.97
|
0.92
|
0.96
|
0.97
|
0.97
|
0.97
|
0.97
|
0.98
|
0.97
|
0.98
|
| Research and Development Expenses |
$282.70 M
|
$244.99 M
|
$227.33 M
|
$201.16 M
|
$131.77 M
|
$140.96 M
|
$123.76 M
|
$78.17 M
|
$70.85 M
|
$50.43 M
|
| General & Administrative Expenses |
$264.12 M
|
$265.54 M
|
$197.52 M
|
$126.28 M
|
$135.80 M
|
$128.95 M
|
$103.65 M
|
$103.96 M
|
$98.02 M
|
$79.54 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$264.12 M
|
$265.54 M
|
$197.52 M
|
$126.28 M
|
$135.80 M
|
$128.95 M
|
$103.65 M
|
$103.96 M
|
$98.02 M
|
$79.54 M
|
| Other Expenses |
$2.44 M
|
$11.39 M
|
$0.00
|
$0.00
|
$100.79 M
|
-$314.00 K
|
-$474.00 K
|
$1.11 M
|
-$264.00 K
|
-$296.00 K
|
| Operating Expenses |
$549.26 M
|
$521.93 M
|
$424.85 M
|
$327.44 M
|
$368.36 M
|
$269.91 M
|
$227.41 M
|
$182.13 M
|
$168.87 M
|
$129.97 M
|
| Cost And Expenses |
$557.00 M
|
$533.38 M
|
$429.27 M
|
$331.26 M
|
$374.48 M
|
$275.15 M
|
$232.94 M
|
$185.73 M
|
$173.42 M
|
$132.15 M
|
| Interest Income |
$17.82 M
|
$21.77 M
|
$6.28 M
|
$1.99 M
|
$5.00 M
|
$10.06 M
|
$5.50 M
|
$3.23 M
|
$3.98 M
|
$7.75 M
|
| Interest Expense |
$11.18 M
|
$11.33 M
|
$11.01 M
|
$19.68 M
|
$19.05 M
|
$18.83 M
|
$9.81 M
|
$4.42 M
|
$4.73 M
|
$0.00
|
| Depreciation & Amortization |
$43.56 M
|
$38.53 M
|
$20.72 M
|
$12.75 M
|
$24.58 M
|
$20.41 M
|
$18.67 M
|
$17.80 M
|
$16.14 M
|
$13.39 M
|
| EBITDA |
-$265.77 M |
-$326.25 M |
-$299.42 M |
-$184.46 M |
-$145.16 M |
-$107.21 M |
-$73.39 M |
-$38.67 M |
-$38.79 M |
$129.46 M |
| EBITDA Ratio |
-1.14
|
-2.25
|
-2.74
|
-1.4
|
-0.73
|
-0.61
|
-0.45
|
-0.25
|
-0.29
|
1.3
|
| Operating Income Ratio |
-1.39
|
-2.67
|
-2.92
|
-1.51
|
-0.89
|
-0.57
|
-0.49
|
-0.35
|
-0.44
|
-0.51
|
| Total Other Income/Expenses Net |
$3.32 M
|
$12.03 M
|
-$11.34 M
|
-$17.46 M
|
-$12.63 M
|
-$46.64 M
|
-$21.83 M
|
-$30.19 M
|
-$23.86 M
|
$156.22 M
|
| Income Before Tax |
-$320.51 M
|
-$376.11 M
|
-$331.16 M
|
-$216.88 M
|
-$188.79 M
|
-$146.45 M
|
-$101.87 M
|
-$58.36 M
|
-$57.58 M
|
$105.47 M
|
| Income Before Tax Ratio |
-1.37
|
-2.59
|
-3.03
|
-1.65
|
-0.95
|
-0.84
|
-0.62
|
-0.38
|
-0.43
|
1.06
|
| Income Tax Expense |
$120.00 K
|
$223.00 K
|
$313.00 K
|
$409.00 K
|
-$19.36 M
|
-$21.00 K
|
$811.00 K
|
$1.37 M
|
-$9.68 M
|
-$11.77 M
|
| Net Income |
-$321.55 M
|
-$111.40 M
|
-$278.48 M
|
-$180.09 M
|
-$169.43 M
|
-$146.43 M
|
-$102.68 M
|
-$59.73 M
|
-$47.90 M
|
$117.24 M
|
| Net Income Ratio |
-1.38
|
-0.77
|
-2.54
|
-1.37
|
-0.85
|
-0.84
|
-0.63
|
-0.39
|
-0.36
|
1.17
|
| EPS |
-4.08 |
-1.5 |
-4.37 |
-3.01 |
-3.56 |
-3.46 |
-2.54 |
-1.54 |
-1.29 |
3.49 |
| EPS Diluted |
-4.08 |
-1.5 |
-4.37 |
-3.01 |
-3.56 |
-3.46 |
-2.54 |
-1.54 |
-1.25 |
3.17 |
| Weighted Average Shares Out |
$78.89 M
|
$74.27 M
|
$63.76 M
|
$59.83 M
|
$47.54 M
|
$42.34 M
|
$40.42 M
|
$38.77 M
|
$37.00 M
|
$33.56 M
|
| Weighted Average Shares Out Diluted |
$78.89 M
|
$74.27 M
|
$63.76 M
|
$59.83 M
|
$47.54 M
|
$42.34 M
|
$40.43 M
|
$38.77 M
|
$38.29 M
|
$37.58 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
